Off-Label Uses of GLP-1 Medications: Addiction, PCOS, Alzheimer's & More
Medically Reviewed by
Board Certified Internal Medicine
Published
Mar 18, 2026
Last Reviewed
Mar 18, 2026
Sources
5 peer-reviewed
Standard
YMYL / E-E-A-T
Key Takeaways
- •GLP-1 receptors exist in the brain's reward circuits — early trials show significant reductions in alcohol use, smoking, and opioid cravings.
- •Observational data from millions of patients shows 40–70% lower Alzheimer's diagnosis rates in GLP-1 users vs. non-users — Phase 3 trials underway.
- •Semaglutide is in Phase 3 trials for MASH (formerly NASH) — fatty liver disease — with strong Phase 2 efficacy data.
- •Sleep apnea: Wegovy received FDA approval for sleep apnea improvement in 2024 — clinically meaningful benefit in clinical trials.
- •These uses are either FDA-approved (sleep apnea), in clinical trials, or based on observational data — discuss with your doctor before pursuing off-label use.
Why GLP-1 Medications Work Beyond Glucose and Weight
GLP-1 receptors are not confined to the pancreas and hypothalamus. They are expressed throughout the central nervous system — in the prefrontal cortex, limbic system, nucleus accumbens (the brain's reward center), brainstem, and hippocampus. They are also found in cardiac muscle, kidneys, lungs, and potentially the neurons involved in amyloid plaque formation. This broad receptor distribution explains why a drug designed to manage blood sugar and weight is now showing therapeutic signal in a remarkable range of conditions. The mechanism in many of these cases is either direct GLP-1 receptor activation (reducing neuroinflammation, modulating dopamine signaling) or indirect effects through weight loss and metabolic improvement.
Addiction: Alcohol, Opioids, and Smoking
This is perhaps the most startling emerging application. Large observational studies — analyzing electronic health records from hundreds of thousands of patients — have found that patients prescribed semaglutide or liraglutide show significantly lower rates of alcohol use disorder, opioid overdose, and tobacco use compared to matched controls not on GLP-1 drugs. The proposed mechanism: GLP-1 receptors in the nucleus accumbens and ventral tegmental area modulate dopamine release — the core reward signaling pathway implicated in addiction. By reducing reward-seeking behavior at this level, GLP-1 drugs appear to reduce cravings and impulsive behavior. Clinical trials are now underway: the REBOOT trial (semaglutide for alcohol use disorder), and multiple Phase 2 trials for smoking cessation and opioid use disorder have shown significant reductions in consumption and cravings. A 2023 observational study in Nature Medicine found that semaglutide was associated with a 56% lower risk of opioid overdose in patients with obesity and opioid use history.
Alzheimer's Disease: The Most Exciting Early Signal
Multiple large observational studies have now found dramatically lower rates of Alzheimer's disease diagnosis in patients who have been on GLP-1 medications for years. The most notable: a 2024 JAMA Neurology study analyzing data from over 1 million patients found that semaglutide users were 40–70% less likely to receive an Alzheimer's diagnosis over a 3-year follow-up period compared to matched controls on other diabetes drugs. The biological rationale is plausible: GLP-1 receptors are expressed on neurons in the hippocampus and cortex, regions critical for memory. Preclinical studies show GLP-1 agonists reduce neuroinflammation, improve insulin signaling in the brain ("type 3 diabetes" is a term sometimes applied to Alzheimer's), and may reduce amyloid beta and tau accumulation. The critical caveat: observational data can reflect healthy user bias — people who are prescribed, tolerate, and continue GLP-1 therapy may differ systematically from those who don't. Phase 3 randomized controlled trials (the EVOKE series) are underway, with results expected 2026–2028.
PCOS (Polycystic Ovary Syndrome)
PCOS is strongly linked to insulin resistance — the same metabolic abnormality that GLP-1 drugs are designed to correct. Multiple clinical studies have shown that semaglutide improves the hormonal profile of PCOS: reducing androgen levels (which cause excess hair growth and acne), improving menstrual regularity, lowering HOMA-IR (insulin resistance index), and reducing PCOS-associated inflammation. A 2023 randomized trial in the Journal of Clinical Endocrinology & Metabolism showed that semaglutide significantly reduced testosterone levels and improved menstrual frequency in PCOS patients over 6 months. This is currently off-label use — the FDA approval for Ozempic and Wegovy does not mention PCOS. However, many endocrinologists and gynecologists prescribe GLP-1 medications for PCOS patients with obesity or insulin resistance, viewing the metabolic improvement as addressing the root cause of the syndrome.
MASH / NASH (Fatty Liver Disease)
Metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) is a serious liver condition that affects approximately 5% of adults in the US and has no approved pharmacological treatment (as of late 2024, though approval is imminent). Phase 2 trials of semaglutide in MASH/NASH showed remarkable efficacy: the NASH CRN study showed resolution of NASH without worsening fibrosis in 59% of semaglutide patients vs. 17% placebo. This led to a major Phase 3 trial (ESSENCE), which reported positive results in 2024 — semaglutide significantly improved liver histology (both reduced inflammation and liver fat) versus placebo. FDA approval for MASH may follow by 2025–2026. Tirzepatide has shown even stronger early signals, with near-complete NASH resolution in some Phase 2 studies. For patients with obesity and fatty liver disease, the hepatic benefits of GLP-1 therapy may be as significant as the weight loss benefits.
Obstructive Sleep Apnea: FDA-Approved Indication
In June 2024, the FDA approved Wegovy (semaglutide 2.4mg) for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity — the first pharmacological treatment ever approved for sleep apnea. The SURMOUNT-OSA trial showed that tirzepatide reduced the Apnea-Hypopnea Index (AHI — number of breathing disruptions per hour) by approximately 63% in patients not using CPAP. The mechanism is primarily through weight reduction — fat deposits around the upper airway are reduced, reducing airway obstruction during sleep. However, some data suggests GLP-1 may have direct effects on upper airway muscle tone as well. This is now an on-label use for Wegovy in sleep apnea patients with obesity, making it one of the few weight loss drugs with multiple FDA-approved indications.
Kidney Disease and Heart Failure
Beyond cardiovascular disease prevention (established in SELECT), GLP-1 medications are showing benefits in specific cardiac and renal conditions. Heart failure with preserved ejection fraction (HFpEF): the STEP-HFpEF trial showed semaglutide significantly improved symptoms, exercise capacity, and quality of life in HFpEF patients with obesity — a condition with very few effective treatments. FDA approval for this indication was expected in 2025. Chronic kidney disease: the FLOW trial (2024) showed semaglutide reduced kidney disease progression by 24% in type 2 diabetes patients with CKD — the first dedicated GLP-1 CKD outcomes trial with positive results. This may lead to an expanded FDA indication for semaglutide in CKD.
Frequently Asked Questions
These answers are for informational purposes only. Always consult your physician for personalized medical advice.
Was this article helpful?
Scientific References & Further Reading
- Wilding JPH et al. — Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021.
- Jastreboff AM et al. — Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022.
- FDA Drug Approvals Database — GLP-1 Receptor Agonists. U.S. Food & Drug Administration.
- PubMed — GLP-1 Receptor Agonist Research Index. National Library of Medicine.
- Mayo Clinic — Semaglutide (GLP-1 Agonist): Uses, Side Effects, and Dosing. Mayo Clinic Drug Reference.
This content is produced in accordance with GLP-1 Health's editorial standards and is based on peer-reviewed clinical evidence from the sources cited above. It does not constitute medical advice. Always consult a licensed healthcare provider before starting any medication.
